TransCode Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
FY EPS (est.)
-$0.31next fiscal year
Monitoring Framework
Key Performance Indicators
TTX-MC138 Phase 2a Patient Enrollment Quarterly0.0
Cash and Cash Equivalents Quarterly12.8MTarget: Sufficient to fund operations through year-end 2026
Watch Items
- Nasdaq Minimum Bid Price ComplianceTrigger: Share price consistently below $1.00 or failure to meet other listing requirementsAction: Monitor shareholder votes on preferred stock conversions and potential reverse stock splits to maintain listing compliance.
- Standby Equity Purchase Agreement (SEPA) DrawdownsTrigger: Capital runway depletion below 6 monthsAction: Utilize the Yorkville SEPA facility for up to $14 million in equity sales and $6 million in convertible notes to extend the cash runway.
Research as of 20 Jun 2026